Isovaleric Acidemia (IVA) Treatment Industry Insights 2025 – Market Forecast for Executives and Planners
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Isovaleric Acidemia (IVA) Treatment Market Size Changed, over the years?
The market for treatment of isovaleric acidemia (IVA) has shown significant expansion in past years. It is projected to increase from $0.60 billion in 2024 to $0.63 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 5.8%. Factors contributing to this growth during the historical period are the heightened awareness of uncommon metabolic disorders, an increased number of newborn screening initiatives, growth in government support for uncommon diseases, amplified attention on enzyme replacement therapies, and a surge in demand for prompt diagnosis and genetic counseling.
How Much Will the Isovaleric Acidemia (IVA) Treatment Market Be Worth in 2029?
Strong expansion is predicted in the isovaleric acidemia (IVA) treatment market, with projections suggesting it could reach $0.79 billion by 2029, boasting a compound annual growth rate (CAGR) of 5.8%. This anticipated surge over the forecast period can be tied to several factors such as increased reliance on gene therapy treatments, a rise in funding for rare disease research, development of new treatment alternatives, heightened collaboration between biotech companies and research institutions as well as an increased emphasis on personalized medicine for metabolic conditions. Trends to watch in the forecast period encompass advancements in genetic testing technologies, sophisticated drug delivery systems for metabolic treatments, breakthroughs in enzyme replacement formulations, the creation of targeted gene editing tools, and progress in newborn screening methodologies.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24269&type=smp
Which is the Largest Company in the Isovaleric Acidemia (IVA) Treatment Market?
Major companies operating in the isovaleric acidemia (IVA) treatment market are Nestlé Health Science S.A., BioMarin Pharmaceutical Inc., GenScript Biotech Corporation, Nutricia Advanced Medical Nutrition, Rocket Pharmaceuticals Inc., REGENXBIO Inc., uniQure N.V., Vitaflo International Ltd., Orchard Therapeutics plc, Editas Medicine Inc., Cambrooke Therapeutics Inc., Recordati Rare Diseases Inc., Abbott Nutrition, Targeted Medical Pharma Inc., Solace Nutrition LLC, Nutricia Metabolics, Bluebird Bio Inc., Verve Therapeutics Inc., Abeona Therapeutics Inc., CRISPR Therapeutics AG
What Are the Main Market Drivers in the Isovaleric Acidemia (IVA) Treatment Industry?
The escalating rate of metabolic disorders is anticipated to fuel the expansion of the isovaleric acidemia (IVA) treatment market. Metabolic disorders disrupt the regular metabolic functions, impacting the conversion of food into energy in our bodies. These disorders, including conditions like diabetes mellitus, hypothyroidism, hyperthyroidism, phenylketonuria (PKU), galactosemia, maple syrup urine disease (MSUD), and others, are often the result of lifestyle habits like poor nutrition and lack of physical activity. Treatment for isovaleric acidemia helps manage these metabolic disorders by dissipating toxic substances in the body, reinstating normal metabolic processes and avoiding complications like neurological damage. For example, as per the American Diabetes Association’s November 2023 data, around 25.5 million U.S. citizens were diagnosed with diabetes in 2022, making up 7.6% of the total population. Hence, the mounting frequency of metabolic disorders propels the isovaleric acidemia (IVA) treatment market’s growth. Increasing cognizance of rare genetic disorders is also projected to spur the advancement of the isovaleric acidemia (IVA) treatment market. These disorders, caused by gene mutations and affecting a small number of individuals, are gaining recognition due to enhanced diagnostic tools and comprehensive genetic screening programs. Treatment for isovaleric acidemia aids management of these rare genetic disorders by offering a custom diet, amino acid supplementation, and occasionally mediations. This treatment approach helps prevent metabolic crises and boosts the quality of life for affected individuals. For example, the World Health Organization (WHO) indicated in February 2023 that birth abnormalities lead to 240,000 newborn deaths within the first 28 days each year, and an additional 170,000 deaths in children aged 1 month to 5 years. Moreover, a February 2023 study by the US-based Rady Children’s Institute for Genomic Medicine found that 41% of infant deaths were linked to single-locus (Mendelian) genetic diseases. Hence, the growing prevalence of metabolic disorders drives the expansion of the isovaleric acidemia (IVA) treatment market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24269&type=smp
How Is the Isovaleric Acidemia (IVA) Treatment Market Segments Structured?
The isovaleric acidemia (IVA) treatment market covered in this report is segmented –
1) By Type: Classical Isovaleric Acidemia, Moderate Isovaleric Acidemia, Non-classical Isovaleric Acidemia
2) By Treatment: Dietary Management, Enzyme Replacement Therapy, Gene Therapy, Pharmacological Treatment
3) By Route of Administration: Oral, Injectable
4)By End-user: Hospitals, Clinics, Homecare Settings
Subsegments:
1) By Classical Isovaleric Acidemia: Dietary Management, Carnitine Supplementation, Glycine Supplementation, Emergency Management, Gene Therapy (Investigational)
2) By Non-classical Isovaleric Acidemia: Observation and Preventive Care, Mild Dietary Modifications, Occasional Supplementation, Genetic Counseling and Monitoring
3) By Moderate Isovaleric Acidemia: Protein-restricted Diet, Intermittent Carnitine/Glycine Therapy, Periodic Monitoring and Supportive Care, Acute Episode Management
Access The Full Report Here:
Which Global Regions Offer the Highest Growth in the Isovaleric Acidemia (IVA) Treatment Market?
North America was the largest region in the isovaleric acidemia (IVA) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the isovaleric acidemia (IVA) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/customise?id=24269&type=smp
This Report Delivers Insight On:
1. How big is the isovaleric acidemia (iva) treatment market, and how is it changing globally?
2. Who are the major companies in the isovaleric acidemia (iva) treatment market, and how are they performing?
3. What are the key opportunities and risks in the isovaleric acidemia (iva) treatment market right now?
4. Which products or customer segments are growing the most in the isovaleric acidemia (iva) treatment market?
5. What factors are helping or slowing down the growth of the isovaleric acidemia (iva) treatment market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
